Latest Tweet

"All our officers are now carrying BolaWrap in the field" - Chief Keith Creter of Brewster Police Department in Ohio gives a demo of the #BolaWrap.

Full story by Amy Knapp at the Independent: https://indeonline.com/story/news/2021/01/15/brewster-wooster-police-wrapping-up-suspects-non-lethal-bolawrap/4147727001/

https://twitter.com/WrapTechInc/status/1350097839117000707

Cardiff Oncology Presents Data that Continues to Demonstrate the Clinical Benefit of Onvansertib in KRAS-Mutated mCRC and Initial Findings from its Expanded Access Program

https://www.prnewswire.com/news-releases/cardiff-oncology-presents-data-that-continues-to-demonstrate-the-clinical-benefit-of-onvansertib-in-kras-mutated-mcrc-and-initial-findings-from-its-expanded-access-program-301209151.html

Latest Tweet

A study found that patients with severe #COVID19 and secondary BSI were sicker upon admission, had longer hospital stays, and poorer outcomes. T2 Panels can ID primary COVID-19 and secondary bacterial and fungal infections. #SARS_CoV_2 #Sepsis #IDSA

https://twitter.com/T2Bio/status/1349744469231468544

One World Pharma Receives Colombian Approval for Five THC Strains
Approvals Allow Company to Seek Sales to European Market

LAS VEGAS, NV, Jan. 14, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- One World Pharma Inc. (OTC: OWPC), “OWP,” a U.S. based, fully licensed, pure-play hemp and cannabis ingredient producer in Colombia, has received official approval and registration from Colombia’s Agricultural Institute (ICA) for five (5) of the Company’s proprietary THC genetic strains. This builds upon the Company’s ongoing genetics program and adds to the approvals previously received for three CBD strains in 2020.

This will allow One World Pharma to now apply for both Supplementary THC quota for 2021 and ordinary quota for 2022, which when approved will greatly expand the Company’s potential commercial opportunities serving the global medical market including countries such as Germany, Switzerland, Italy, and Portugal which have legal THC medical use applications.

“It is a tremendous achievement by our team to secure these essential and difficult to obtain approvals,” stated Isiah Thomas, Chief Executive Officer, One World Pharma. “It speaks to the quality of our proprietary, high quality genetic strains and our processes and to our strong relationship with the Colombian government and its agencies.”

“But most importantly, these approvals now unlock access to a vast international market that we’ve been waiting to enter,” added Thomas.

https://www.otcmarkets.com/stock/OWPC/news/story?e&id=1785199

Winners, Inc. Subsidiary VegasWINNERS Launch Text Messaging Service With Prompt.io(TM) to Provide Its Customers With Real Time Sports Gambling Research, Data, Advice, Analysis and Predictions

LAS VEGAS, NV / ACCESSWIRE / January 12, 2021 / Winners, Inc. (OTC PINK:WNRS) subsidiary VegasWINNERS, Inc. announces the launch of its text messaging service with Prompt.io to provide its customers with interactive texting for real time sports gambling research, data, advice, analysis and predictions. VegasWINNERS will be amongst the first handicappers to utilize texting. The company sees this as a competitive advantage, since 90% of text messages are read within 3 minutes of being received. This is significantly more interaction than email which, by contrast, sees only a 5% interaction rate as successful.

Wayne Allyn Root, CEO of Winners, Inc. stated "Our customers can just text us the word or phrase they desire, and our system will reply within moments. We believe the level of customer interaction will be unparalleled. VegasWINNERS customers can type words or phrases such as "lines for today," "NFL scores," "tell me every score in the Packer game as it happens," "buy the pick for the night game," for example and so many other specific personally generated words and/or phrases. Vegas Winners is ushering in a new paradigm for sports fans."

https://www.otcmarkets.com/stock/WNRS/news/story?e&id=1782871

EWST nice.

T2 Biosystems T2SARS-CoV-2™ Panel Proves Effective Amid Global Rise in Variants of the SARS-CoV-2 Virus

Panel can detect multiple variants of the SARS-CoV-2 virus, including those most recently identified in the United Kingdom, South Africa, and the U.S.

LEXINGTON, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that its T2SARS-CoV-2™ Panel—a molecular diagnostic test that detects SARS-CoV-2, the virus responsible for COVID-19 infections—is capable of detecting the multiple variants of the SARS-CoV-2 virus most recently identified in the United Kingdom, South Africa, and the United States.

“As new strains of the COVID-19 virus emerge, it is critical that we ensure our technology continues to be an effective diagnostic solution during the ongoing pandemic,” said T2 Biosystems’ President and CEO, John Sperzel. “I’m proud that we can confidently say, after extensive analysis, that our T2SARS-CoV-2 Panel, which has demonstrated clinical sensitivity of 95 percent and specificity of 100 percent, can continue to help impact lives by detecting multiple variants of the SARS-CoV-2 virus.”

Both the variants identified in the United Kingdom (B.1.1.7) and South Africa (B.1.351) contain multiple mutations, most reflected in the S gene, which encodes the spike protein. To confirm that the T2SARS-CoV-2 Panel would detect these variants and other potential mutations of SARS-CoV-2 viruses, an in silico analysis was performed using genome sequences available in the National Center for Biotechnology Information (NCBI) nucleotide database and GISAID database.

Over 42,000 genome sequences for SARS-CoV-2 were evaluated for alignment with primer and probe sequences from T2SARS-CoV-2 Panel. This analysis demonstrated that the T2SARS-CoV-2 Panel should detect 99.99% of all SARS-CoV-2 viruses based on sequence alignments. A specific analysis of sequences for B.1.1.7 and B.1.351 variants confirmed that the T2SARS-CoV-2 Panel should be able to detect these variants.

The T2SARS-CoV-2 Panel provides results in under two hours utilizing an upper respiratory swab sample. The test runs on the Company’s FDA-cleared and fully-automated T2Dx® Instrument, which is capable of performing seven tests simultaneously and up to sixty samples per day.

The same T2Dx Instrument is also capable of running the FDA-cleared T2Bacteria® Panel and T2Candida® Panel. These panels are the only FDA-cleared assays for the detection of sepsis-causing bacterial and fungal pathogens directly from whole blood in three to five hours, without the need to wait days for blood culture results. By providing quicker results, the panels enable clinicians to target therapy faster for their patients suspected of sepsis, often before the second dose of antimicrobial medicine is administered, leading to better patient outcomes, improved antimicrobial stewardship, and reductions in length of stay in the hospital.

These additional panels remain especially clinically relevant during the pandemic, as data suggests that the COVID-19 virus can lead to sepsis, and death.

https://www.globenewswire.com/news-release/2021/01/11/2156669/0/en/T2-Biosystems-T2SARS-CoV-2-Panel-Proves-Effective-Amid-Global-Rise-in-Variants-of-the-SARS-CoV-2-Virus.html

Latest Tweet

We are excited to announce that we have partnered with Werfen as our new distributor in the United Kingdom! Our international distributors play a crucial role in bringing T2 Biosystems technology to countries around the globe. #sepsis #sepsisawareness #T2Bio #Werfen #AMR

https://twitter.com/T2Bio/status/1348679034469838848

Exicure Granted Two Fast Track Designations for Cavrotolimod (AST-008) from the U.S. Food and Drug Administration

https://www.businesswire.com/news/home/20210111005348/en/Exicure-Granted-Two-Fast-Track-Designations-for-Cavrotolimod-AST-008-from-the-U.S.-Food-and-Drug-Administration

Sounds great!

Hope so buddy.

Winners, Inc. Announces Ticker Symbol Change From "GOOOD" To "WNRS" On OTC Markets Effective January 6th, 2021

LAS VEGAS, NV / ACCESSWIRE / January 5, 2021 / Winners, Inc. (OTC PINK:GOOOD) which provides sports betting enthusiasts with high-quality analysis, research, data, guidance and professional advice through its subsidiary VegasWINNERS, Inc., announced today that effective January 6th , 2021, the Company's ticker symbol on OTC Markets will change from "GOOOD" to "WNRS".

"Our ticker symbol change is aligned with our strategic evolution as a leading global sports betting advisor," stated Tom Terwilliger, CEO of Winners, Inc.

"We've come a long way, both operationally and financially since the VegasWINNERS acquisition this past summer and have positioned our rebranded company, Winners, Inc., at the forefront of the emerging global sports gambling industry," continued Mr. Terwilliger. "Our new ticker symbol marks the completion of this corporate transformation and will serve to further enhance our visibility in the market."

The sports betting market was valued at US $85.047 billion in 2019. The sports betting market is projected to witness dramatic growth based on expansion of legal sports gambling and the need of the governments of numerous U.S. states and foreign countries around the globe for more tax revenues.

The market is also poised to grow on account of the rising popularity of international sports events around the globe- such as NFL, NBA, NASCAR, UFC (mixed martial arts) and Soccer, as well as the rising commercialization of sports events- including sponsorships by gaming companies.

Historically, betting on sports was only legal in the State of Nevada and/or bets with bookmakers or offshore sportsbooks. In 2018, the United States Supreme Court decision allowing States to legalize sports betting changed everything, creating tremendous opportunity. Twenty-six states plus Washington DC. have already legalized wagering on sports and/or are pending taking bets in 2021, with 14 additional states under consideration this calendar year. See: https://www.actionnetwork.com/news/legal-sports-betting-united-states-projections#LegalAccepting.

All but five states have legislation pending to allow legal sports gambling.

https://www.otcmarkets.com/stock/GOOOD/news/story?e&id=1777812

Symbol Change from GOOOD to WNRS, effective 01/06/2021 per DL.

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

Thanks for sharing.

CWRK ready to roll. MMs been working very hard to keep her down. Three days in a row of new 52-week highs and nice volume too.

“USA Equities Corp (USAQ), Announces Revenues of $120,000 for the 4th Quarter of 2020 and Projects Revenues in excess of $300,000 for the 1st Quarter of 2021

WEST PALM BEACH, FL, Dec. 30, 2020 (GLOBE NEWSWIRE) -- USA EQUITIES CORP. (OTCQB: USAQ) (the “Company,” “we,” or “our”) announced today that its revenues for the fourth quarter of 2020 would be approximately $120,000 and that its revenues would exceed $300,000 in the first quarter of 2021.

We introduced our QHSLab, Software as a Service (SaaS) platform, to 159 medical practices in June 2020. Through September, physicians in these practices provided 374 allergy patients with a QHSLab-generated allergen immunotherapy prescription, generating an estimated $664,608 in revenue for these physicians’ practices. In November, building on the capabilities of our QHSLab, we began shipping allergy diagnostic related products and immunotherapy treatments to these physicians in response to their requests based upon courses of treatment recommended for their patients by QHSLab. Our revenue in the fourth quarter will be $120,000 as a result of these sales. Based upon orders in hand and reasonably anticipated, revenues from our allergy diagnostic test kits and treatment programs should exceed $300,000 in the first quarter of 2021. Revenues from this program should continue to increase thereafter as we increase the number of physicians and medical practices utilizing QHSLab.

Based on our QHSLab allergy treatment system’s success, we intend to increase our revenues by charging physicians a monthly subscription fee for the use of QHSLab. USAQ plans to introduce these physicians to additional point of care diagnostic, digital medicine, and treatments that our physician clients can use and prescribe. They will be paid under existing government and private insurance programs, based upon analyses conducted utilizing QHSLab.

The revenues we generated in the fourth quarter of 2020 and anticipated revenue in the first quarter of 2021 far exceed the revenue levels assumed by the equity research firm, Litchfield Hills Research, when it released its first analyst coverage report on USAQ. Litchfield Hills continue to rate our stock as a “buy” under its three-tiered rating system, with a target price of $5.00 per share.

https://www.otcmarkets.com/stock/USAQ/news/story?e&id=1774878

I agree. OLB due for uptick IMO.

Exicure Provides Neuroscience Pipeline Update at Virtual R&D Day

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Exicure, Inc. (NASDAQ: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, announced that it will host a virtual R&D Day on Thursday, January 7th, 2021 from 09:00 am to 10:30 am ET to discuss Exicure’s neuroscience pipeline, including its lead program for Friedreich’s Ataxia which has progressed into IND-enabling studies.

Exicure’s Scientific Advisory Board member Dr. Susan Perlman and the CEO of the Friedreich’s Ataxia Research Alliance (FARA) Jennifer Farmer, will join Exicure’s leadership team in discussing the company’s progress in Friedreich’s Ataxia and its expanding neuroscience pipeline.

Susan L. Perlman, MD, is a Clinical Professor in the Department of Neurology at the David Geffen School of Medicine at UCLA, where she is also the Director of Clinical Trials and Director, Ataxia Clinic for UCLA’s Neurogenetics program. She is a member of the Medical Research Advisory Board for the National Ataxia Foundation and has been a primary investigator for several Friedreich’s Ataxia trials.

Jennifer Farmer, MS is the CEO of the Friedreich’s Ataxia Research Alliance (FARA). Since joining FARA in 2006, she has led FARA’s efforts to establish clinical research infrastructure and clinical trial readiness, grown the research grant program, and led efforts to engage bio-pharmaceutical companies in drug discovery and development for Friedreich’s Ataxia.

A live webcast will be available in the Events and Presentations section of Exicure’s website on January 7, 2021 at 09:00 am ET. An archived version will be available on the company website following the event. Additional information can be found here: https://troutaccess.com/index.php/c/ExicureResearchDay2021

https://www.otcmarkets.com/stock/XCUR/news/story?e&id=1773972

To all the good people at Ihub, have a merry and safe Christmas!

Oops, after I Sell my shares.

ITDN will probably find merger deal after I see my shares...lol

Transphorm Announces Closing of $15 Million Private Placement of Common Stock

Positioned to Capitalize on Significant Market Opportunities and Growing Adoption of GaN Power Conversion Devices

GOLETA, Calif.--(BUSINESS WIRE)-- Transphorm, Inc. (OTCQB: TGAN)—a pioneer in and global supplier of high reliability, high performance gallium nitride (GaN) power conversion products—today announced the closing of a common stock only private placement of 5,000,000 shares at a price of $3.00 per share, resulting in gross proceeds to Transphorm of $15.0 million, before deducting placement agent commissions, financial advisor fees and other offering expenses.

“We are very pleased with the strong support from the financial community for Transphorm’s vision and the representative growth opportunities for our high-voltage GaN power devices,” stated Mario Rivas, Chief Executive Officer. “In addition to strengthening Transphorm’s overall financial position, completion of this funding enables us to aggressively ramp production in support of secured design-ins for fast charging power adapter applications, while simultaneously expanding the sampling and qualification of our Gen IV and Gen V SuperGaN® products for EV automotive applications. Entering 2021, we are well positioned to benefit from industry megatrends, such as 5G communications and vehicle electrification, due to the increasing demand for high reliability, high performance GaN power conversion devices that can deliver the features and functionality required by a growing cross-section of strategic partners and customers.”

Transphorm intends to utilize the net proceeds to scale volume shipments of GaN products for the fast charging power adapter, server, communication and gaming power supply markets as well as converters/inverters for industrial and renewable applications, expanded sampling and qualification in EV automotive applications, growth of its epi wafer business, as well as working capital to support general operations.

The securities sold in the private placement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state or other jurisdiction’s securities laws, and may not be resold absent registration under, or exemption from registration under, the Securities Act. Transphorm has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock issued and sold in the private placement within 30 days of the closing of the private placement.

https://www.otcmarkets.com/stock/TGAN/news/story?e&id=1773511

Winners, Inc. Subsidiary VegasWINNERS to Commence National Radio Campaign With Pete Rose, Major League Baseballs All-Time Hits Leader and Legendary Sports Handicapper Wayne Allyn Root

LAS VEGAS, NV / ACCESSWIRE / December 23, 2020 / Winners, Inc. (OTC PINK:GOOOD) subsidiary VegasWINNERS Inc., which provides sports betting enthusiasts with high quality analysis, research, data, guidance and professional advice, announced today that it will be commencing its national radio campaign with spokesperson Pete Rose, Major League Baseball's all-time hits leader, and VegasWINNERS CEO Wayne Allyn Root. Radio spots will begin airing in select markets across the U.S. after Christmas.

Rose played baseball professionally from 1963 to 1986 and is the all-time MLB leader in hits (4,256), games played (3,562), at-bats (14,053), singles (3,215), and career plate appearances (15,890). He won three World Series rings, three batting titles, one Most Valuable Player Award, two Gold Gloves, the Rookie of the Year Award, and also made 17 All-Star appearances at an unequaled five positions (second baseman, left fielder, right fielder, third baseman, and first baseman). Despite these impressive accomplishments, Rose remains outside of baseball's Hall of Fame for admitting to betting on baseball as a manager.

VegasWINNERS founder and CEO Wayne Allyn Root stated "Sports gambling is now a legal and growing business. Revenues are exploding in states across the USA. It's a business about winning. Amateur and professional gamblers alike need the best research, analysis and professional winning advice. That's why I founded VegasWINNERS: to provide that winning advice. Pete Rose embodies winning. He has the most hits in baseball history and the most combined wins as a player and coach in sports history. We are thrilled to have Pete Rose on our team."

VegasWINNERS recently launched its newly designed website, providing sports betting enthusiasts with high quality analysis, research, data, guidance and professional advice. Leading the group of world class handicappers on VegasWINNERS is Wayne Allyn Root, the man who has single-handedly merged sports gambling into Wall Street investment advice, and is the only sports handicapper awarded a star on the Las Vegas Walk of Stars.

https://www.otcmarkets.com/stock/GOOOD/news/story?e&id=1773026

Not sure of any NVSOS filings for AS increase. Last filing 7/15/20 shows 100M AS. OTCM SS date 11/30/20. Must be some kind of new math...lol

Trading resumed yesterday not too long after the halt. Trended up, then closed well below HOD. Was hoping maybe some news would have followed, but nothing yet.

Hope news is good for KYNS.

Hoping 'limited licenses cartoon panda characters' and 'children’s educational tools' are Big sales, translating into Big payoff for shareholders.

KYNS News

Keynes Technology Group, Inc. (KYNS) Enters Into a Material Definitive Agreement With Both Pandaland Holdings, Ltd. And KidsDNA, Inc.

LOS ANGELES, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Keynes Technology Co. Ltd (OTC:KYNS), a Nevada Corporation (the “Company”) which trades on the OTC Markets under the symbol “KYNS”, entered into a “Stock Exchange Agreement” to acquire 95.33% of Pandaland Holding (HK) Ltd., a corporation organized under the laws of Hong Kong.

In consideration for the purchase, Keynes Technology Co. LTD will issue to Pandaland Holdings, Ltd. 150,000,000 shares of common stock and 35,000,000 shares of preferred stock of KYNS. Upon completion of the acquisition, Pandaland Holdings, ltd. will be a majority owned subsidiary of the Company.

Additionally, on December 18, 2020, the Company entered into a “Stock Exchange Agreement” to acquire all the outstanding common stock of KidsDNA, Inc., a corporation organized under the Laws of Taiwan.

In consideration for the purchase, Keynes Technology Co. LTD will issue to KidsDNA, Inc. 100,000,000 shares of the common stock and 25,000,000 shares of preferred stock of KYNS. Upon completion of the acquisition, KidsDNA, Inc. will be a wholly-owned subsidiary of the Company.

https://www.otcmarkets.com/stock/KYNS/news/story?e&id=1772626

Keynes Technology Group, Inc. (KYNS) Enters Into a Material Definitive Agreement With Both Pandaland Holdings, Ltd. And KidsDNA, Inc.

LOS ANGELES, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Keynes Technology Co. Ltd (OTC:KYNS), a Nevada Corporation (the “Company”) which trades on the OTC Markets under the symbol “KYNS”, entered into a “Stock Exchange Agreement” to acquire 95.33% of Pandaland Holding (HK) Ltd., a corporation organized under the laws of Hong Kong.

In consideration for the purchase, Keynes Technology Co. LTD will issue to Pandaland Holdings, Ltd. 150,000,000 shares of common stock and 35,000,000 shares of preferred stock of KYNS. Upon completion of the acquisition, Pandaland Holdings, ltd. will be a majority owned subsidiary of the Company.

Additionally, on December 18, 2020, the Company entered into a “Stock Exchange Agreement” to acquire all the outstanding common stock of KidsDNA, Inc., a corporation organized under the Laws of Taiwan.

In consideration for the purchase, Keynes Technology Co. LTD will issue to KidsDNA, Inc. 100,000,000 shares of the common stock and 25,000,000 shares of preferred stock of KYNS. Upon completion of the acquisition, KidsDNA, Inc. will be a wholly-owned subsidiary of the Company.

https://www.otcmarkets.com/stock/KYNS/news/story?e&id=1772626

OLB Group Shares Halted On Volatility; Shares Up 26% ($5.37)

Transphorm Announces Pricing of $15 Million Private Placement of Common Stock

GOLETA, Calif.--(BUSINESS WIRE)-- Transphorm, Inc. (OTCQB: TGAN)—a pioneer in and global supplier of high reliability, high performance gallium nitride (GaN) power conversion products—today announced the pricing of a private placement of 5,000,000 shares of its common stock at a price of $3.00 per share, for expected gross proceeds to Transphorm of $15.0 million, before deducting placement agent commissions, financial advisor fees and other offering expenses.

The closing of the private placement is expected to occur on or about December 22, 2020, subject to the satisfaction of customary closing conditions. Transphorm intends to utilize the net proceeds to scale the continued ramp of new design-ins and volume shipments of GaN products for the fast charging power adapter, server, power supply and other markets, expanded sampling and qualification of products for EV automotive applications, growth of its epi wafer business as well as working capital to support general operations.

The securities to be sold in the private placement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state or other jurisdiction’s securities laws, and may not be resold absent registration under, or exemption from registration under, the Securities Act. Transphorm has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock to be issued and sold in the private placement within 30 days of the closing of the private placement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

Loop Capital Markets LLC and Spartan Capital Securities, LLC acted as placement agents for the private placement. B. Riley Securities, Inc. and Craig-Hallum Capital Group LLC acted as financial advisors for the private placement.

https://www.otcmarkets.com/stock/TGAN/news/story?e&id=1772202

Exicure Announces Issuance of Two New U.S. Patents and A New Patent Allowance Covering Cavrotolimod Through 2034

Patents and patent application provide additional coverage for company’s therapeutic for patients with advanced solid tumors

December 21, 2020 09:15 AM Eastern Standard Time
CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced that the U.S. Patent and Trademark Office has issued two new patents, No.10,792,251 (the ‘251 patent) and No. 10,837,018 (the ‘018 patent), and allowed U.S. patent application 14/907,430 (the ‘430 application), further strengthening the Company’s intellectual property position and coverage for the Company’s therapeutic product candidate, cavrotolimod.

The ‘018 patent and the ‘430 application, both titled, “Spherical Nucleic Acid-based Constructs as Immunostimulatory Agents for Prophylactic and Therapeutic Use,” covers nanoparticles with a corona of CpG oligonucleotides and their methods for treating cancer.

The ‘251 patent, jointly owned by the Company and Northwestern University, titled, “Liposomal Particles, Methods of Making Same and Uses Thereof,” is directed to liposomal nanoparticles with toll-like receptor 9 (TLR9) agonist oligonucleotides and methods for treating cancer.

“The two issued patents and the soon-to-be-issued patent demonstrate our commitment to developing cavrotolimod, which is currently in a Phase 2 clinical trial for the potential treatment of Merkel cell carcinoma and cutaneous squamous cell carcinoma,” said David Giljohann, Chief Executive Officer of Exicure. “We are pleased with cavrotolimod’s development to date and excited about its potential to address unmet need for patients living with these rare forms of skin cancers.”

https://www.businesswire.com/news/home/20201221005412/en/Exicure-Announces-Issuance-of-Two-New-U.S.-Patents-and-A-New-Patent-Allowance-Covering-Cavrotolimod-Through-2034

WRAP Announces New International Orders and Growing Number of Domestic Orders

BolaWrap Recently Successfully Deployed in San Mateo

TEMPE, Ariz., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Wrap Technologies, Inc. (the “Company” or “WRAP”) (Nasdaq: WRAP), an innovator of modern policing solutions, announced today international reorders and a growing number of new and repeat domestic orders for BolaWrap® products and accessories.

WRAP recently received several international reorders totaling over 600 BolaWrap devices, plus cartridges and accessories. The Company expects to fulfill these orders by the end of the month.

During the last thirty days, WRAP has also received over 50 new orders and more than 15 reorders for domestic law enforcement agencies, including:

Agency in Virginia: purchased 20 devices
Agency in Ohio: purchased 20 devices
Agency in Georgia: purchased 12 devices
Agency in Texas: purchased 10 devices
Agency in Arizona: repeat order, purchased 10 devices
Agency in Indiana: purchased 10 devices
Agency in North Carolina: purchased 10 devices
Agency in Louisiana: purchased 10 devices

BolaWrap was deployed in the field last Tuesday by the San Mateo County Sheriff’s Office to safely apprehend a noncompliant homeless man, as reported by Jason Green of The Mercury News. Media coverage of the story can be found here.

This field deployment comes on the heels of a successful BolaWrap field usage captured on bodycam by Beaufort Police Department just days prior.

“Despite the social, political, financial and healthcare challenges seen by law enforcement in 2020, we are proud of the commitment our partner agencies are making to increase public safety and safely de-escalate potentially higher levels of force,” said Tom Smith, President and Interim CEO of WRAP Technologies. “We are seeing increases in both agency adoption and successful field deployments, signaling what we believe is part of a changing tide in the way law enforcement approaches non-compliant but non-violent subjects.”

http://www.globenewswire.com/news-release/2020/12/21/2148671/0/en/WRAP-Announces-New-International-Orders-and-Growing-Number-of-Domestic-Orders.html

Exicure initiated with an Outperform at BMO Capital

BMO Capital analyst Do Kim initiated coverage of Exicure with an Outperform rating and $6.00 price target. The company's opportunities in neurological diseases are under-appreciated in spite of the compelling validation for oligonucleotides to correct genetic drivers of hereditary central nervous system disorders, the analyst tells investors in a research note. Kim adds that given the lead drug XCUR-FXN's pre-clinical data and the filing in 2021 to support clinical benefit, he sees a "compelling" risk-reward opportunity for Exicure.

Read more at:
https://thefly.com/n.php?id=3215717

FACT, Inc Changes Ticker Symbol to Reflect Strategic Refocus

Toronto, Ontario--(Newsfile Corp. - December 16, 2020) - FACT Inc. (formerly Tiburon International Trading Inc.) (OTC Pink: FCTI) (the "Company" or "FACT, Inc") is pleased to announce today that it has changed its ticker symbol to align with the recent strategic changes within the Company, including the refocusing of the Company on verification, reporting and management of fine art and collectibles for the global market. The name change was approved on November 18, 2020 by the Board of Directors and the majority shareholder. The Company expects that the shares of common stock will begin trading on the OTC Markets under the new symbol "FCTI" on December 16, 2020.

"We are pleased to announce a rebranding of the Company that reflects the strategic realignment of the Company's business objective around changing the way art is authenticated, tracked and managed across multiple sectors throughout the fine art and collectible industry," said Patricia Trompeter, Chief Operating Officer of FACT, Inc. "We want our company name and symbol to embody the Company's DNA as well as our breakthrough products and services that will revolutionize security for the art market."

https://www.otcmarkets.com/stock/FCTI/news/story?e&id=1768134

https://www.otcmarkets.com/stock/FCTI/security

https://factsecured.com/

CurrencyWorks, Odyssey Trust and the Canadian Securities Exchange (CSE) Announce a Security Token Reporting System

Toronto, Ontario and Los Angeles CA, Dec. 16, 2020 (GLOBE NEWSWIRE) -- CurrencyWorks Inc. (“CWRK” or “CurrencyWorks”) (TSXV and OTCQB: CWRK), builds and operates FinTech Platforms as a Service for digital currencies, security tokens and digital assets, today announced the development of a security token reporting system that can be immediately deployed to drive value for public issuers. The blockchain platform has been developed through a partnership between CurrencyWorks, the Canadian Securities Exchange (the “CSE”) and Odyssey Trust Company (“Odyssey Trust”).

A unique security token can be associated with each issuer on the CSE that opts into the platform, enabling Odyssey Trust to provide issuers with deeper reporting information and enhanced transfer agent services. The blockchain reporting system will run parallel to the existing clearing and settlement services for CSE issuers.

CurrencyWorks will provide various integration services, as well as Testnet and smart contract platforms. These will be used to test and validate the process of issuing security tokens.

Cameron Chell, Chairman of CurrencyWorks, stated: “Security tokens are gaining increasing acceptance in jurisdictions around the world, providing issuers and investors with an innovative way to create value and liquidity. We are pleased to partner with Odyssey Trust and the CSE to launch this system.”

Bruce Elliott, President of CurrencyWorks, said: "This exciting announcement highlights the tremendous value inherent in security tokens. We see security token offerings as an ideal vehicle for resource companies seeking to raise capital by utilizing their reserves, or future sales, without diluting their current equity. They should also be appealing to companies in the pharmaceutical and technology industries as well as any company with a recurring revenue model.”

Richard Carleton, CEO of the CSE, said: “The CSE is committed to leading international exchange markets in the listing and trading of regulated security tokens, and we are pleased to be collaborating with CurrencyWorks and Odyssey Trust to support the infrastructure enabling security token offerings in Canada. We have seen tremendous interest in security tokens among both existing and potential CSE issuers.”

Jenna Kaye, CEO of Odyssey Trust, added: “We believe this innovative platform is capable of delivering improved liquidity, greater market access, and long-term efficiencies.”

For more information on this announcement, please contact Bruce Elliott at bruce.elliott@currencyworks.io.

https://www.otcmarkets.com/stock/CWRK/news/CurrencyWorks-OdysseyTrust-and-the-Canadian-Securities-Exchange-CSE-Announce-a-Security-Token-Reporting-System?id=283673

WRAP Acquires Virtual Reality Training Provider, NSENA Inc.

Acquisition Enhances BolaWrap Law Enforcement Training with Immersive 3D Scenarios and Creates New Opportunities for Fully-Integrated Training Solutions for First Responders

TEMPE, Ariz., Dec. 16, 2020 (GLOBE NEWSWIRE) -- WRAP Technologies, Inc. (the “Company” or “WRAP”) (Nasdaq: WRAP), an innovator of modern policing solutions, announced today that it has entered into and closed an Asset Purchase Agreement with NSENA Inc., a developer and provider of a law enforcement training platform employing immersive computer graphics virtual reality with proprietary software, hardware and content.

https://www.globenewswire.com/news-release/2020/12/16/2146220/0/en/WRAP-Acquires-Virtual-Reality-Training-Provider-NSENA-Inc.html#:~:text=TEMPE%2C%20Ariz.%2C%20Dec.,a%20law%20enforcement%20training%20platform

Nice to see Litchfield is sticking to their $5 PPs target for USAQ.

Quote:

We believe USAQ is undervalued and we support that belief with two valuation techniques, both of which generate
approximately the same figure: $5.00. For the purposes of determining our price target we use a discounted future
earnings model.

New Bodycam Footage Captures BolaWrap® Deployment in South Carolina

http://www.globenewswire.com/news-release/2020/12/15/2145385/0/en/New-Bodycam-Footage-Captures-BolaWrap-Deployment-in-South-Carolina.html

Nice.